期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型降糖药利拉鲁肽的临床应用 被引量：4

原文传递
导出
摘要 肠促胰素类药物利拉鲁肽（1iraglutide，商品名Victoza）具有显著降糖、改善β细胞功能、降低低血糖风险、减少体质量、降低收缩压等作用，在改善血糖控制的同时，为糖尿病患者带来多种降糖外益处，解决了现有降糖治疗存在的一些问题，在糖尿病治疗领域将拥有广泛的应用空间。
作者 张相林
机构地区 卫生部中日友好医院药学部临床药学室
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第24期2001-2003,共3页 Chinese Journal of Hospital Pharmacy
关键词 2型糖尿病 肠促胰素 GLP-1 利拉鲁肽 DPP IV
分类号 R969 [医药卫生—药理学]
  • 相关文献

参考文献19

  • 1Russell-Jones D. Molecular, pharmacological and clinical as pects of liraglutide, a once-daily human GLP / analogue [J]. Mol Cell Endocrinol, 2(/09, 297(1- 2):137- 140.
  • 2Knudsen LB, Knudsen SM, Wilken M, et al. Plasma protein binding of NN221l, a long-acting derivative of GLP-1, is im portant for its efficacy [J]. Diabetes, 2003, 52:A321- A322.
  • 3Elbr nd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmaeodynamies, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide I derivative, in healthy male subjects [J]. Diabetes Care, 2002, 25:1398 - 1404.
  • 4Marre M, Shaw J, Brandle M, et al. I.iraglutide, a once daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in sub jects with Type 2 diabetes (LEAI>1 SU) [J]. Diabetic Medi cine, 2009, 26:268-278.
  • 5Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAI) (liraglutide effect and action in diabetes) 2 study [J]. Diabe tes (;are, 2(}09, 32:84-90.
  • 6Garber A, Henry R, Rather R, et al. Liraglutide versusglimepiride monotherapy for type 2 diabetcs (LEAD-3 Mono) :a randomised, 52 week, phase Ⅲ, double-blind, paralMtreatment trial [J]. I.ancet, 2009, 373(9662):473- 481.
  • 7Zinman B, Gerieh J, Buse JB, el al. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog I.iraglutide in Combi nation With Metfomlin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met + TZD) [J]. Diabetes Care, 2009, 32:1224- 1230.
  • 8Russel-Jones D, Vaag A, Schmitz O, et al. I.iraglutide vs in- sulin glargine and placebo in combination with metformin andsulfonylurea therapy in type 2 diabetes mellitus (LEAI)-5 met + SU) : a randomised controlled trial [J]. Diabetologia, 2009, 52(10) :2046- 2055.
  • 9Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6) [J]. Lancet, 2009, 374(9683):39-47.
  • 10Matthews DR, Marre M, Le Thi TD, etal. Liraglutide, a hu- man GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes [J]. Diabetologia, 2008, 51 (Suppl 1 ) : 892.

同被引文献57

引证文献4

二级引证文献30

中国医院药学杂志
2012年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部